News

Samsung Biologics and Biogen Idec Announce Formation of Biosimilars Joint Venture Samsung Bioepis

Published: February 29, 2012

News

Samsung Biologics and Biogen Idec Announce Formation of Biosimilars Joint Venture Samsung Bioepis

Published: February 29, 2012

Read time:

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Samsung Biologics and Biogen Idec Announce Formation of Biosimilars Joint Venture Samsung Bioepis"

First Name*

Last Name*

Email Address*

Country*

Company Type*

Job Function*

Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Christopher Hansung Ko, previously Senior Vice President of Samsung Strategic Business Development, has been named the CEO of Samsung Bioepis. The joint venture’s Board of Directors will consist of five directors and one auditor.

The strategic collaboration between Samsung Biologics and Biogen Idec will enable Samsung Bioepis to build the capabilities needed to develop high-quality biosimilars.

Construction of Samsung Bioepis’ research and development center, located at Samsung Biologics’ site in Song-do Incheon, Korea, has started and will be completed by the end of the year.

Chosen for you